Kaltoft, Margit Staum
Novo Nordisk (Denmark)
2 papers on CoChatORCID 0000-0001-8899-0405
Most cited papers
- Verified
The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial
Dhatariya, K., Bain, S. C., Buse, J. B., Simpson, R., Tarnow, L., Kaltoft, M. S., Stellfeld, M., Tornøe, K., Pratley, R. E., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Diabetes Care
Diabetic Foot Ulcer Assessment and ManagementDiabetes Treatment and Management
Cited by 141
- Verified
Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: lIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial
Blonde, L., Belousova, L., Fainberg, U., Garcia‐Hernandez, P. A., Jain, S. M., Kaltoft, M. S., Mosenzon, O., Nafach, J., Palle, M. S., & Rea, R. (2020) · Diabetes, Obesity and Metabolism
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 54
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free